Ikena Oncology, Inc. announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co. have recommended that stockholders vote 'FOR' the issuance of shares related to the proposed merger with Inmagene Biopharmaceuticals. These recommendations were made ahead of Ikena's Annual Meeting of Stockholders scheduled for July 15, 2025. The vote pertains to 'PROPOSAL 1' concerning the issuance of shares in connection with the merger.
Mark Manfredi, PhD, Chief Executive Officer of Ikena, highlighted the potential of IMG-007 to create value for shareholders across the immunological and inflammatory (I&I) disease space. He noted the recent progress in the global Phase 2B study for IMG-007 in atopic dermatitis. The Ikena Board remains committed to the merger with Inmagene, viewing it as a strategic fit.
All stockholders as of the record date, May 22, 2025, are eligible to vote at the upcoming Annual Meeting. The positive recommendations from these influential advisory services provide a strong signal to shareholders regarding the strategic merits of the merger.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.